187 related articles for article (PubMed ID: 36323699)
21. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
22. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
[TBL] [Abstract][Full Text] [Related]
23. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
[TBL] [Abstract][Full Text] [Related]
24. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
[TBL] [Abstract][Full Text] [Related]
25. HSD17B13: A Potential Therapeutic Target for NAFLD.
Zhang HB; Su W; Xu H; Zhang XY; Guan YF
Front Mol Biosci; 2021; 8():824776. PubMed ID: 35071330
[TBL] [Abstract][Full Text] [Related]
26. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5.
Gao X; Nan Y; Zhao Y; Yuan Y; Ren B; Sun C; Cao K; Yu M; Feng X; Ye J
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1512-1519. PubMed ID: 28919478
[TBL] [Abstract][Full Text] [Related]
27. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
Cansby E; Kulkarni NM; Magnusson E; Kurhe Y; Amrutkar M; Nerstedt A; Ståhlman M; Sihlbom C; Marschall HU; Borén J; Blüher M; Mahlapuu M
FASEB J; 2019 Sep; 33(9):9974-9989. PubMed ID: 31173506
[TBL] [Abstract][Full Text] [Related]
29. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
30. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
31. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
32. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease.
Sim WC; Lee W; Sim H; Lee KY; Jung SH; Choi YJ; Kim HY; Kang KW; Lee JY; Choi YJ; Kim SK; Jun DW; Kim W; Lee BH
Metabolism; 2020 Jan; 102():154000. PubMed ID: 31678070
[TBL] [Abstract][Full Text] [Related]
34. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
35. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
36. Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.
Liu S; Sommese RF; Nedoma NL; Stevens LM; Dutra JK; Zhang L; Edmonds DJ; Wang Y; Garnsey M; Clasquin MF
Nat Commun; 2023 Aug; 14(1):5158. PubMed ID: 37620305
[TBL] [Abstract][Full Text] [Related]
37. Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice.
Adam M; Heikelä H; Sobolewski C; Portius D; Mäki-Jouppila J; Mehmood A; Adhikari P; Esposito I; Elo LL; Zhang FP; Ruohonen ST; Strauss L; Foti M; Poutanen M
FASEB J; 2018 Jun; 32(6):3434-3447. PubMed ID: 29401633
[TBL] [Abstract][Full Text] [Related]
38. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
Yu HM; Chung HK; Park KS
Biochem Biophys Res Commun; 2021 Jun; 558():57-63. PubMed ID: 33895552
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte Nuclear Factor 4α Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice).
Xu Y; Zhu Y; Hu S; Xu Y; Stroup D; Pan X; Bawa FC; Chen S; Gopoju R; Yin L; Zhang Y
Hepatology; 2021 Jun; 73(6):2251-2265. PubMed ID: 33098092
[TBL] [Abstract][Full Text] [Related]
40. Expression and localization of HSD17B13 along mouse urinary tract.
Zhang H; Chang J; Dai Z; Wang Q; Qiao R; Huang Y; Ma B; Jiang J; Zhu C; Su W; Zhang X; Guan Y
Am J Physiol Renal Physiol; 2024 May; ():. PubMed ID: 38779753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]